Clinical trial
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
NCT04458259 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT04458259 |
|---|---|
| Title | Study of PF-07265807 in Participants With Metastatic Solid Tumors. |
| Official title | A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | PF-07265807, Sasanlimab, Axitinib |
| Enrollment | 88 |
| Start date | Sep 24, 2020 |
| Primary completion | Nov 15, 2024 |
| Completion | Nov 15, 2024 |
| First posted | Jul 7, 2020 |
| Last update posted | Aug 28, 2025 |
| Countries | Canada, Italy, Japan, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: